These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 23994973

  • 1. Efficacy of infliximab in patients with intestinal Behçet's disease refractory to conventional medication.
    Kinoshita H, Kunisaki R, Yamamoto H, Matsuda R, Sasaki T, Kimura H, Tanaka K, Naganuma M, Maeda S.
    Intern Med; 2013; 52(17):1855-62. PubMed ID: 23994973
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: Efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study.
    Hibi T, Hirohata S, Kikuchi H, Tateishi U, Sato N, Ozaki K, Kondo K, Ishigatsubo Y.
    Medicine (Baltimore); 2016 Jun; 95(24):e3863. PubMed ID: 27310969
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Efficacy of infliximab in intestinal Behçet's disease: a Korean multicenter retrospective study.
    Lee JH, Cheon JH, Jeon SW, Ye BD, Yang SK, Kim YH, Lee KM, Im JP, Kim JS, Lee CK, Kim HJ, Kim EY, Kim KO, Jang BI, Kim WH.
    Inflamm Bowel Dis; 2013 Aug; 19(9):1833-8. PubMed ID: 23702810
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The 2nd edition of consensus statements for the diagnosis and management of intestinal Behçet's disease: indication of anti-TNFα monoclonal antibodies.
    Hisamatsu T, Ueno F, Matsumoto T, Kobayashi K, Koganei K, Kunisaki R, Hirai F, Nagahori M, Matsushita M, Kobayashi K, Kishimoto M, Takeno M, Tanaka M, Inoue N, Hibi T.
    J Gastroenterol; 2014 Jan; 49(1):156-62. PubMed ID: 23955155
    [Abstract] [Full Text] [Related]

  • 12. Refractoriness of intestinal Behçet's disease with myelodysplastic syndrome involving trisomy 8 to medical therapies - our case experience and review of the literature.
    Toyonaga T, Nakase H, Matsuura M, Minami N, Yamada S, Honzawa Y, Hukata N, Yoshino T, Chiba T, Okazaki K.
    Digestion; 2013 Jan; 88(4):217-21. PubMed ID: 24247154
    [Abstract] [Full Text] [Related]

  • 13. Anti-Tumor Necrosis Factor Therapy in Intestinal Behçet's Disease.
    Park J, Cheon JH.
    Gut Liver; 2018 Nov 15; 12(6):623-632. PubMed ID: 29788675
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study.
    Niccoli L, Nannini C, Benucci M, Chindamo D, Cassarà E, Salvarani C, Cimino L, Gini G, Lenzetti I, Cantini F.
    Rheumatology (Oxford); 2007 Jul 15; 46(7):1161-4. PubMed ID: 17478466
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Comparative Study of Infliximab Versus Adalimumab in Refractory Uveitis due to Behçet's Disease: National Multicenter Study of 177 Cases.
    Atienza-Mateo B, Martín-Varillas JL, Calvo-Río V, Demetrio-Pablo R, Beltrán E, Sánchez-Bursón J, Mesquida M, Adan A, Hernández MV, Hernández-Garfella M, Valls-Pascual E, Martínez-Costa L, Sellas-Fernández A, Cordero-Coma M, Díaz-Llopis M, Gallego R, García-Serrano JL, Ortego-Centeno N, Herreras JM, Fonollosa A, Garcia-Aparicio ÁM, Maíz-Alonso O, Blanco A, Torre-Salaberri I, Fernandez-Espartero C, Jovaní V, Peiteado D, Pato E, Cruz J, Férnandez-Cid C, Aurrecoechea E, García-Arias M, Castañeda S, Caracuel-Ruiz MA, Montilla-Morales CA, Atanes-Sandoval A, Francisco F, Insua S, González-Suárez S, Sanchez-Andrade A, Gamero F, Linares Ferrando LF, Romero-Bueno F, García-González AJ, González RA, Muro EM, Carrasco-Cubero C, Olive A, Prior Á, Vázquez J, Ruiz-Moreno O, Jiménez-Zorzo F, Manero J, Muñoz Fernandez S, Fernández-Carballido C, Rubio-Romero E, Pages FA, Toyos-Sáenz de Miera FJ, Martinez MG, Díaz-Valle D, López Longo FJ, Nolla JM, Álvarez ER, Martínez MR, González-López JJ, Rodríguez-Cundin P, Hernández JL, González-Gay MA, Blanco R.
    Arthritis Rheumatol; 2019 Dec 15; 71(12):2081-2089. PubMed ID: 31237427
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of infliximab rescue therapy in patients with chronic refractory pouchitis: a multicenter study.
    Barreiro-de Acosta M, García-Bosch O, Souto R, Mañosa M, Miranda J, García-Sanchez V, Gordillo J, Chacon S, Loras C, Carpio D, Maroto N, Menchén L, Rojas-Feria M, Sierra M, Villoria A, Marin-Jimenez I, Grupo joven GETECCU.
    Inflamm Bowel Dis; 2012 May 15; 18(5):812-7. PubMed ID: 21826765
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Long-term Follow-up and Optimization of Infliximab in Refractory Uveitis Due to Behçet Disease: National Study of 103 White Patients.
    Martín-Varillas JL, Atienza-Mateo B, Calvo-Rio V, Beltrán E, Sánchez-Bursón J, Adán A, Hernández-Garfella M, Valls-Pascual E, Sellas-Fernández A, Ortego N, Maíz O, Torre I, Fernández-Espartero C, Jovani V, Peiteado D, Valle DD, Aurrecoechea E, Caracuel MA, García-González AJ, Álvarez ER, Vegas-Revenga N, Demetrio-Pablo R, Castañeda S, González-Gay MA, Hernández JL, Blanco R, Ricardo Blanco on behalf of the Spanish Collaborative Group of Refractory Behçet’s Disease.
    J Rheumatol; 2021 May 15; 48(5):741-750. PubMed ID: 33004539
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.